Sandoz drugs Jubbonti and Wyost are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to ongoing patent litigation between the two companies.
The charges, filed in Philadelphia federal court, allege that Teva conspired with four other generic drug companies to fix prices, rig bids and allocate customers. Teva - which the Justice Department and New York's state government also sued this month for unrelated allegations - said it rejected the allegations.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A federal appeals court upheld two key patents covering Amgen's Enbrel, thus further preventing Novartis' generics unit from launching its biosimilar. However, an analyst wrote that the probability of Sandoz overturning the decision is low.
The company is adding several new products to its pipeline, including treatments for chronic pain and migraines, and voice-based biomarkers.
Spectrum said the FDA had accepted its application for Rolontis, which had shown non-inferiority to Amgen's Neulasta in Phase III testing. However, oncologists expressed mixed opinions about the drug.
A panel discussion at the DTx East conference in Boston discussed whether partnerships between digital health and drugmakers were "a match made in heaven."
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In exchange for ceding rights to develop, sell and market Akili's two lead products in Japan and Taiwan to Shionogi, Akili will receive $20 million upfront and up to $105 million in additional payments dependent on reaching certain development and commercial milestones.
The Canadian company's shares reached a high price after it signed a framework agreement with Novartis's generics arm that would enable global commercialization.
The reSET-O prescription mobile application is directed at supporting patients using buprenorphine as a medicinal aid in treatment to overcome opioid addiction.
The study can assure clinicians that Sandoz's Zarxio works just as well in febrile neutropenia as originator Amgen's Neupogen, author says in interview.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Ernie Chambers cites case of Alvogen suing Nevada as grounds for lawsuit to stop use of its products in lethal injection.
Market forecast rosy, though market in United States remains young.
On Friday, the Food and Drug Administration approved the first biosimilar, marking an initial big step foward in changing the climate of the drug market in the United States. Time to save some money. Zarxio, produced by Sandoz, Inc. – a division of Novartis, is a drug that is designed to help the body produce […]
Pink eye drug AzaSite, a major component of Inspire Pharmaceutical‘s (NASDAQ:ISPH) portfolio and one of the key products sought by Merck (NYSE:MRK) in its $430 million acquisition of the North Carolina company, could soon be facing generic competition. Inspire said in a regulatory filing that generics company Sandoz notified the company that it has submitted […]